IHeartSense DX - INFANT - Pre Order Now For mid-September 2026

IHeartSense DX — Infant

Pre-Order Now · Estimated Release: mid-September 2026 (subject to regulatory clearance)

Product Description

IHeartSense DX — Infant is a first-of-its-kind AI-governed cardiac ultrasound screening system for infants, designed to support safe, focused cardiac screening outside clinical settings.

The system is purpose-built for infants and does not rely on a trained operator. Parents or carers do not adjust imaging parameters or interpret images. Instead, AI fully governs probe positioning, ultrasound power, capture timing, and safety, enforcing strict limits appropriate for infant use.

IHeartSense DX — Infant uses a fully wireless handheld ultrasound probe paired with a mobile application. Guided by simple on-screen prompts, the carer places the probe as instructed while the system automatically determines when sufficient data has been captured.

To reduce complexity and risk, the product does not display raw ultrasound images. It provides clear, screening-level outputs only, such as:

No abnormality detected

Abnormality detected – review advised

Urgent escalation advised

The infant system incorporates ultra-low ultrasound exposure, seconds-long capture windows, and a mechanical positioning interface that helps enforce safe placement and contact. The device automatically stops if safety conditions are not met.

IHeartSense DX — Infant is intended for screening and escalation awareness, not diagnosis, and is designed to complement—not replace—professional medical care.

Key Characteristics

AI-governed operation with no manual imaging controls

Wireless handheld ultrasound hardware

Ultra-low exposure and short capture duration

Mechanical positioning support for safe use

Interpreted screening outputs, not images

Patent-pending platform

IHeartSense DX — Infant introduces a new category of parent-operated infant cardiac screening, bringing controlled, AI-managed ultrasound assessment into the home with safety at the forefront.

Estimated release mid-September 2026, subject to regulatory approval.